Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer

Executive Summary

Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.

Advertisement

Related Content

GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer
Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits
Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer
AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel